Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential.
Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G.
Stapleton NM, et al. Among authors: andersen jt.
Nat Commun. 2011 Dec 20;2:599. doi: 10.1038/ncomms1608.
Nat Commun. 2011.
PMID: 22186895
Free PMC article.